Abstracts (complete list) - Wissenschaft Online

R. Riedl, J. Sommer, K. Prinz, A. Egyed, C. Schellack, A. von Gabain, E. Nagy, K.
Lingnau
IC31TM: a novel adjuvant that potently activates Type I
immune responses
The novel adjuvant IC31TM consists of a combination of a negatively-charged synthetic
oligodeoxynucleotide and a positively-charged peptide. IC31TM is characterized by a
broad mechanism of action, as well as an excellent safety profile. Detailed analyses
showed that the immunostimulatory effect of IC31TM is mediated via the TLR9/MyD88dependent
signaling pathway of the innate immune system. Additionally, both depot
formation at the injection site as well as sustained activation of antigen presenting cells,
followed by antigen uptake and processing, is likely responsible for the induction of the
observed IC31TM-mediated antigen-specific immune responses. It could be shown in
mice that IC31TM induces strong T cell responses activating both CD4+ helper T cells as
well as CD8+ cytotoxic T cells. In addition, strong humoral immune responses with
increased antibody titers are generated by IC31TM. Because of its activation of innate
immune cell types, such as NK cells and DC, as well as its stimulation of Type I T cell
responses, IC31TM may show broad applicability to the treatment of infectious diseases
and tumors.